PL3160464T3 - 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych - Google Patents

6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych

Info

Publication number
PL3160464T3
PL3160464T3 PL15744478T PL15744478T PL3160464T3 PL 3160464 T3 PL3160464 T3 PL 3160464T3 PL 15744478 T PL15744478 T PL 15744478T PL 15744478 T PL15744478 T PL 15744478T PL 3160464 T3 PL3160464 T3 PL 3160464T3
Authority
PL
Poland
Prior art keywords
hydroxybuspirone
treatment
movement disorders
disorders
movement
Prior art date
Application number
PL15744478T
Other languages
English (en)
Inventor
John Bondo Hansen
Mikael S. THOMSEN
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contera Pharma Aps filed Critical Contera Pharma Aps
Publication of PL3160464T3 publication Critical patent/PL3160464T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15744478T 2014-06-26 2015-06-25 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych PL3160464T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA201470389 2014-06-26
DKPA201470388 2014-06-26
DKPA201570102 2015-02-26
DKPA201570101 2015-02-26
EP15744478.7A EP3160464B1 (en) 2014-06-26 2015-06-25 6-hydroxybuspirone for use in the treatment of movement disorders
PCT/DK2015/050186 WO2015197079A1 (en) 2014-06-26 2015-06-25 Use of buspirone metabolites

Publications (1)

Publication Number Publication Date
PL3160464T3 true PL3160464T3 (pl) 2018-12-31

Family

ID=53761914

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15744478T PL3160464T3 (pl) 2014-06-26 2015-06-25 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych

Country Status (13)

Country Link
US (1) US11478476B2 (pl)
EP (1) EP3160464B1 (pl)
JP (1) JP6634445B2 (pl)
KR (2) KR102527805B1 (pl)
CN (1) CN107635555B (pl)
AU (1) AU2015281448B2 (pl)
CA (1) CA2950469C (pl)
DK (1) DK3160464T3 (pl)
ES (1) ES2686529T3 (pl)
HU (1) HUE039750T2 (pl)
PL (1) PL3160464T3 (pl)
PT (1) PT3160464T (pl)
WO (1) WO2015197079A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
KR20200035035A (ko) * 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
AU2018310882C1 (en) * 2017-07-31 2021-12-09 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
WO2022013809A2 (en) * 2020-07-17 2022-01-20 Novartis Ag USE OF mGluR5 ANTAGONISTS
AU2021397439A1 (en) * 2020-12-11 2023-07-06 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
JP2024521959A (ja) * 2021-06-09 2024-06-04 プロニラス コーポレイション オピエート離脱又はオピエート再発に関連する状態を治療又は予防する方法
CN113341026A (zh) * 2021-07-02 2021-09-03 北京和合医学诊断技术股份有限公司 Lc_ms_ms检测丁螺环酮及其代谢产物的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
WO1993013766A1 (en) * 1992-01-07 1993-07-22 Merrell Dow Pharmaceuticals Inc. Treatment of involuntary movements with 5ht1a receptor agonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
EP1047436B1 (en) * 1998-01-13 2009-10-21 Synchroneuron, LLC N-acetylhomotaurinates for use in treating hyperkinesias
US20050137206A1 (en) 1999-08-05 2005-06-23 Yevich Joseph P. Method for treatment of anxiety and depression
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
US6593331B2 (en) 2001-04-17 2003-07-15 Laboratories Upsa Method for treatment of pain
EP1417203A4 (en) * 2001-07-24 2005-08-10 Bristol Myers Squibb Co S-6-HYDROXY-BUSPIRONE
EP1408979A4 (en) 2001-07-24 2005-03-23 Bristol Myers Squibb Co R-6-HYDROXY-BUSPIRONE
WO2006092143A1 (en) 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20110183995A1 (en) 2008-06-24 2011-07-28 Neurosearch A/S Eltoprazine for suppression of l-dopa induced dyskinesias
US20120238547A1 (en) 2009-09-07 2012-09-20 Neurosearch A/S 2, 3, 6 - triamino substituted pyridines as kv7 (kcnq) channel modulators
CA2813648C (en) * 2010-10-15 2019-06-25 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
SG11201406690SA (en) 2012-04-18 2014-11-27 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders

Also Published As

Publication number Publication date
EP3160464B1 (en) 2018-07-18
CN107635555A (zh) 2018-01-26
PT3160464T (pt) 2018-10-12
HUE039750T2 (hu) 2019-02-28
WO2015197079A1 (en) 2015-12-30
DK3160464T3 (en) 2018-10-29
JP6634445B2 (ja) 2020-01-22
KR102527805B1 (ko) 2023-04-28
KR20170021848A (ko) 2017-02-28
US20170128446A1 (en) 2017-05-11
CN107635555B (zh) 2021-02-26
ES2686529T3 (es) 2018-10-18
US11478476B2 (en) 2022-10-25
AU2015281448B2 (en) 2020-04-09
AU2015281448A1 (en) 2017-01-05
JP2017519827A (ja) 2017-07-20
EP3160464A1 (en) 2017-05-03
CA2950469C (en) 2022-09-20
CA2950469A1 (en) 2015-12-30
KR20230042131A (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
IL251526A0 (en) Use of cannabidiol in the treatment of multiple sclerosis complex
SG11201607705XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
IL247515A0 (en) Snekribirock for the treatment of leprosy
GB201403093D0 (en) Therapeutic compounds and their use
IL248856B (en) New treatment
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL247589A0 (en) Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PL3215157T3 (pl) Apilimod do stosowania w leczeniu czerniaka
IL246855A0 (en) Materials for use in the treatment of retinitis
GB201402179D0 (en) Surface treatment
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
EP3200795A4 (en) Use of agents for treating fat-related disorders
IL252043A0 (en) A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders
GB201418541D0 (en) Materials for use with general hyperthermia treatment
ZA201408464B (en) Composition for the use in treatment of asthma
GB201415302D0 (en) New therapeutic use
GB201417719D0 (en) New treatment
GB201410387D0 (en) Compounds and their therapeutic use
GB201408384D0 (en) New treatment
GB201403496D0 (en) Compounds and their therapeutic use
GB201400235D0 (en) Treatment
GB201400238D0 (en) Treatment